EPHA3 and glioblastoma: Indeed, Chu et al. [60] demonstrated that anti-EPHA3-modified NPs may potentially serve as a N2B drug carrier for the treatment of glioblastoma, confirming the concept that these systems may well attain the brain tissue to deliver the drug.